Novartis (NVS)
(Delayed Data from NYSE)
$108.13 USD
+1.35 (1.26%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $108.20 +0.07 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$108.13 USD
+1.35 (1.26%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $108.20 +0.07 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.
Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Sarepta's (SRPT) second-quarter 2023 earnings beat estimates. Though total revenues register strong year-over-year growth during the quarter, the same misses the mark.
Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) second-quarter results beat estimates for earnings but misses the mark on sales. Management reiterated its previously-issued financial guidance for 2023.
United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
Vertex (VRTX) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) second-quarter 2023 earnings and sales beat estimates. Based on strong Trikafta uptake, management raises its financial guidance for 2023.
Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Incyte (INCY) reports impressive Q2 earnings on strong uptake in Jakafi and Opzelura sales. The company raises the bottom end of full-year guidance, setting a new range of $2.58-$2.63 billion.
How Will Pfizer's (PFE) Key Drugs Perform in Q2 Earnings?
by Zacks Equity Research
Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q2.
Sanofi (SNY) Beats on Q2 Earnings, Misses Sales, Stock Down
by Zacks Equity Research
Sanofi (SNY) beats second-quarter estimates for earnings but misses the same for sales. It raises the projected earnings growth range for 2023.
Bristol-Myers (BMY) Q2 Earnings, Sales Miss, '23 View Lowered
by Zacks Equity Research
Bristol-Myers' (BMY) second-quarter 2023 earnings and sales miss estimates due to generic erosion for the oncology drug Revlimid. The company also cuts its forecast for 2023.
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
AbbVie's (ABBV) second-quarter 2023 earnings and sales beat estimates. The company raises its EPS guidance. Stock rises post the announcement.
Roche (RHHBY) 1H Revenues, Earnings Down on Lower COVID-19 Test Sales
by Zacks Equity Research
Roche's (RHHBY) performance in the first half of 2023 was ordinary as COVID-19-test sales continue to decline and dent the top line.
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) second-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Pharma Stock Roundup: JNJ, NVS Upbeat Q2 Results, FDA Nod to SNY & AZN RSV Antibody
by Kinjel Shah
FDA approves AstraZeneca (AZN) and Sanofi's (SNY) RSV antibody, Beyfortus. J&J (JNJ) and Novartis (NVS) announce strong second-quarter results.
Here's Why You Should Add Alnylam (ALNY) Stock to Your Portfolio
by Zacks Equity Research
Alnylam's (ALNY) revenues continue to be driven by Amvuttra and Givlaari sales. Its existing collaboration agreement with Regeneron to develop RNAi-based candidates is progressing well.
Company News for Jul 19, 2023
by Zacks Equity Research
Companies In The News Are: SYF, NVS, SCHW, PNC.
Novartis (NVS) Q2 Earnings & Revenues Top, Guidance Raised
by Zacks Equity Research
Novartis (NVS) beats on earnings and sales in the second quarter and raises its annual guidance on strong momentum.
Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Q2 2023 Earnings Season Gathers Pace
by Zacks Equity Research
Q2 2023 Earnings Season Gathers Pace.
Q2 Earnings Week Brings Us Tesla, Netflix & More
by Mark Vickery
Aside from a handful of Wall Street banks and other industry leaders, Q2 numbers are out this week for the first of the FAANGs and Tesla.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Novartis (NVS) Might Surprise This Earnings Season
by Zacks Equity Research
Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Novartis (NVS) to Report Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
When Novartis (NVS) reports second-quarter 2023 results, investor focus is likely to be on updates related to Sandoz's spin-off besides the top- and bottom-line numbers.
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
by Zacks Equity Research
AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.
Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study
by Zacks Equity Research
Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.
Novartis (NVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novartis (NVS) closed at $97.16, marking a +0.63% move from the previous day.